Drug Profile
ET 008
Latest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator Endocrine Technology LLC
- Class
- Mechanism of Action CD4 antigen inhibitors; Complement factor D inhibitors; Complement factor H inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 24 Apr 2007 Discontinued - Preclinical for Anthrax in USA (unspecified route)
- 22 Feb 2002 Preclinical development for Anthrax in USA (Unknown route)